Founded in 2006, Rivus Pharmaceuticals operates in biotechnology/pharmaceuticals. The stock is not listed on any public market.
Rivus Pharmaceuticals has no published valuation.
Rivus Pharmaceuticals is a clinical-stage biopharmaceutical company headquartered in Charlottesville, Virginia, working on cardiometabolic health. Its lead candidate HU6 is an oral therapy for metabolic dysfunction-associated steatohepatitis advancing through the AMPLIFY Phase 2 trial, and a second candidate, RV-8451, an oral GLP-1, is in IND-enabling studies for obesity.
The company launched in 2021 with a $35 million Series A financing. Its Chair of Development, David Grainger, has founded more than 30 biotech companies, including Padlock Therapeutics and Morphogen-IX, which later became part of Centessa Pharmaceuticals.
Listed funds carry late-stage private names. A fund's latest schedule of investments shows whether it holds Rivus Pharmaceuticals.
Often trade at a premium or discount to NAV.
Platforms match existing holders with buyers. Rivus Pharmaceuticals availability at any moment is set by the holders.
High minimums, transfer approval, company right-of-first-refusal.
Valuations, rounds and IPO status for every company in the directory — Rivus Pharmaceuticals included.
The routes section explains what is realistically available for a company at this stage.
No. Rivus Pharmaceuticals is a private company; its shares do not trade on a public exchange.
The closest biotechnology/pharmaceuticals peers are on the competitors page.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
